Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.
Roche commenced operations in the U.S. over 100 years ago and these operations include research and development centers that conduct leading-edge work in advancing disease detection and treatment. Our diagnostics and pharmaceuticals businesses in the U.S. employ more than 20,000 people and generate approximately $10 billion in sales (including Genentech), accounting for about 40% of the Roche Group's global annual revenues.
For further information, please visit http://www.roche.com .
All trademarks used or mentioned in this release are protected by law.
- All documents on the offer to Ventana's shareholders: http://www.roche.com/info070625
Roche Group Media Office
Phone: +41 61 688 8888 / e-mail: email@example.com
-- Daniel Piller (Head of Roche Group Media Office)
-- Baschi Durr
Brunswick Group (for US media)
Phone: +1 212 333 3810
-- Steve Lipin
-- Nina Devlin
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
THIS DOCUMENT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS. THESE
FORWARD- LOOKING STATEMENTS MAY BE IDENTIFIED BY WORDS SUCH AS 'BELIEVES',
'EXPECTS', 'ANTICIPATES', 'PROJEC
Copyright©2007 PR Newswire.
All rights reserved